Is fondaparinux safer than enoxaparin for patients undergoing percutaneous coronary intervention?

被引：0
|
作者：
Elliott M Antman
机构：
[1] EM Antman is the Director of the Samuel A Levine Cardiac Unit at the Brigham and Women's Hospital and Professor of Medicine at Harvard Medical School,
[2] Boston,undefined
[3] MA,undefined
[4] USA.,undefined
来源：
Nature Clinical Practice Cardiovascular Medicine | 2008年 / 5卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：184 / 185
页数：1
相关论文
共 50 条
  • [1] Is fondaparinux safer than enoxaparin for patients undergoing percutaneous coronary intervention?
    Antman, Elliott M.
    [J]. NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2008, 5 (04): : 184 - 185
  • [2] Enoxaparin for anticoagulation in patients undergoing percutaneous coronary intervention
    James, Stefan
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2012, 344
  • [3] Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban
    Zhao X.
    Yang X.-X.
    Ji S.-Z.
    Wang X.-Z.
    Wang L.
    Gu C.-H.
    Ren L.-L.
    Han Y.-L.
    [J]. Military Medical Research, 3 (1)
  • [4] Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban
    Xin Zhao
    Xiao-Xu Yang
    Su-Zhen Ji
    Xiao-Zeng Wang
    Li Wang
    Chong-Huai Gu
    Li-Li Ren
    Ya-Ling Han
    [J]. Military Medical Research, 2016, 3 (02) : 73 - 79
  • [5] Efficacy and safety of fondaparinux versus Enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Results from the OASIS-5 trial
    Mehta, Shamir R.
    Granger, Christopher B.
    Eikelboom, John W.
    Bassand, Jean-Pierre
    Wallentin, Lars
    Faxon, David P.
    Peters, Ron J. G.
    Budaj, Andrzej
    Afzal, Rizwan
    Chrolavicius, Susan
    Fox, Keith A. A.
    Yusuf, Salim
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (18) : 1742 - 1751
  • [6] Reliable anticoagulation with Enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study
    Martin, JL
    Fry, ETA
    Sanderink, GJCM
    Atherley, TH
    Guimart, CM
    Chevalier, PJ
    Ozoux, ML
    Pensyl, CE
    Bigonzi, F
    [J]. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2004, 61 (02) : 163 - 170
  • [7] Intravenous enoxaparin in patients undergoing percutaneous coronary intervention: A Bayesian approach based study
    Pena, PS
    Montalescot, G
    Hulot, JS
    Urien, S
    Collet, JP
    Choussat, R
    Ankri, A
    Lechat, P
    [J]. CIRCULATION, 2004, 110 (17) : 616 - 616
  • [8] Comparison of Original and Generic Enoxaparin for Treatment of Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention
    Vichairuangthum, Kitigon
    Chotenoparatpat, Paiboon
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (12) : S41 - S42
  • [9] Enoxaparin is safer and more effective than unfractionated heparin in contemporary percutaneous coronary interventions
    Diez, JG
    Cheong, B
    Nguyen, VD
    O'Meallie, L
    Alt, E
    [J]. CIRCULATION, 2003, 108 (17) : 569 - 569
  • [10] Combined use of eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: The results of the CRUISE trial
    Bhatt, DL
    Lincoff, AM
    [J]. CIRCULATION, 2001, 104 (17) : 384 - 385
12345